Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase Ia/Ib First-In-Human Clinical Trial to Evaluate the Safety, Tolerability and Initial Anti-Tumor Activity of IMA401, a Bispecific T Cell Engaging Receptor Molecule (TCER®), as Monotherapy or in Combination With Checkpoint Inhibitor in Patients With Recurrent and/or Refractory Solid Tumors.

Next Previous
Trial Profile

A Phase Ia/Ib First-In-Human Clinical Trial to Evaluate the Safety, Tolerability and Initial Anti-Tumor Activity of IMA401, a Bispecific T Cell Engaging Receptor Molecule (TCER®), as Monotherapy or in Combination With Checkpoint Inhibitor in Patients With Recurrent and/or Refractory Solid Tumors.

Status: Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 22 Jul 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs IMA 401 (Primary) ; Pembrolizumab (Primary)
  • Indications Gastric cancer; Head and neck cancer; Lung cancer; Malignant melanoma; Neuroendocrine tumours; Non-small cell lung cancer; Ovarian cancer; Sarcoma; Skin cancer; Solid tumours; Squamous cell cancer
  • Focus Adverse reactions; First in man; Proof of concept
  • Sponsors Immatics N.V.

Most Recent Events

  • 02 Jun 2026 Results presented at the 62nd Annual Meeting of the American Society of Clinical Oncology
  • 31 May 2026 Results published in the Media Release
  • 31 May 2026 According to an Immatics media release, data from the ongoing Phase 1 study of IMA401 will be presented on May 31, 2026, during the Developmental Therapeutics Session - Immunotherapy from 8:00-11:00 am CDT by Martin Wermke, M.D., TU Dresden University of Technology, NCT/UCC Early Clinical Trial Unit, Dresden, Germany (Abstract ID: 2507).

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top